Literature DB >> 6091168

Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79.

M Moore, M H Kaplan, J McPhee, D J Bregman, S W Klein.   

Abstract

In the period 1970 through 1979, the Coxsackie B1, B2, B3, B4, and B5 viruses constituted 24 percent of more than 18,000 enteroviruses isolated and reported through national surveillance. Young children, especially males, were most frequently affected: 48 percent of the national surveillance population were less than 5 years of age, including 30 percent who were less than 1 year old. Among the most frequently reported clinical syndromes associated with B infection were meningitis (in 56 percent of patients with B1-B5 infections), encephalitis (in 15 percent), and respiratory tract disease (in 14 percent). Carditis, a well-known B syndrome, was reported with only 2 percent of B1-B5 infections. Like most enteroviral agents, Group B viruses were isolated primarily during the summer: 87 percent of all these isolations were made during the 5 months from June through October. Although B2, B3, and B4 viruses were isolated at relatively uniform levels each year, B1 and B5 viral illnesses occurred nationwide as explosive epidemics only in certain years. A separate population of B-infected patients, identified by the Nassau County Medical Center (NCMC) Virus Laboratory, East Meadow, N.Y., during the same 10-year period, was studied to compare epidemiologic characteristics and to evaluate in greater detail clinical and laboratory features of B infections. Because of more active solicitation of specimens for testing, ascertainment in the NCMC system was more complete. The most frequently reported clinical findings at NCMC included fever (97 percent of cases), which was biphasic in 27 percent; pharyngitis (85 percent); vomiting (56 percent); headache (49 percent); other respiratory signs and symptoms (44 percent); diarrhea (40 percent); abdominal pain (33 percent); rash (31 percent); and otitis (28 percent). Rash was more frequently associated with younger than with older age groups (P < .01) for all B agents. Overall, throat (T) and rectal (R) swabs had the highest B-positivity rates among known infected patients(83 percent for T and 78 percent for R). Only for T was the positivity rate correlated with the interval between onset of illness and obtaining the specimen (P < .05). B agents grew most quickly from T specimens, but most reliably from R specimens. On the basis of these data,the authors recommend that both T and R specimens be obtained from every patient for whom prompt and reliable laboratory diagnosis of B infection is sought.To the authors' knowledge, these results from 10 years of national surveillance represent the largest surveillance summary of Coxsackie B viruses to date in the literature. Comparison of these results with those reported over the same 10 years by NCMC reflects differences that arise mostly because of differences in ascertainment systems.

Entities:  

Mesh:

Year:  1984        PMID: 6091168      PMCID: PMC1424625     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  33 in total

Review 1.  Coxsackie viruses and the heart.

Authors:  N R Grist; E J Bell
Journal:  Am Heart J       Date:  1969-03       Impact factor: 4.749

Review 2.  An experimental approach to virus myocarditis.

Authors:  A M Lerner
Journal:  Prog Med Virol       Date:  1965

3.  Coxsackie B myopericarditis in adults.

Authors:  W G Smith
Journal:  Am Heart J       Date:  1970-07       Impact factor: 4.749

4.  Coxsackie B viral myocarditis and valvulitis identified in routine autopsy specimens by immunofluorescent techniques.

Authors:  G E Burch; S C Sun; H L Colcolough; R S Sohal; N P DePasquale
Journal:  Am Heart J       Date:  1967-07       Impact factor: 4.749

5.  The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VII. Observations on viral excretion, seroimmunity, intrafamilial spread and illness association in coxsackie and echovirus infections.

Authors:  A Kogon; I Spigland; T E Frothingham; L Elveback; C Williams; C E Hall; J P Fox
Journal:  Am J Epidemiol       Date:  1969-01       Impact factor: 4.897

6.  Coxsackie B pericarditis.

Authors:  N M Bennett
Journal:  Med J Aust       Date:  1966-07-23       Impact factor: 7.738

7.  A continuing surveillance of enterovirus infection in healthy children in six United States cities. II. Surveillance enterovirus isolates 1960-1963 and comparison with enterovirus isolates from cases of acute central nervous system disease.

Authors:  J E Froeschle; P M Feorino; H M Gelfand
Journal:  Am J Epidemiol       Date:  1966-05       Impact factor: 4.897

8.  Clinical and epidemiological features of Coxsackie group B virus infections.

Authors:  M S Artenstein; F C Cadigan; E L Buescher
Journal:  Ann Intern Med       Date:  1965-10       Impact factor: 25.391

9.  Coxsackie pericarditis.

Authors:  N M Bennett; J A Forbes
Journal:  Am Heart J       Date:  1967-09       Impact factor: 4.749

10.  [Acute virus myocarditis in infants and children].

Authors:  A Windorfer; F C Sitzmann
Journal:  Dtsch Med Wochenschr       Date:  1971-07-09       Impact factor: 0.628

View more
  19 in total

Review 1.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  Immunoglobulin M capture immunoassay in investigation of coxsackievirus B5 and B6 outbreaks in South Australia.

Authors:  P N Goldwater
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

3.  Coxsackie B2 Virus Infection Causing Multiorgan Failure and Cardiogenic Shock in a 42-Year-Old Man.

Authors:  Kali A Hopkins; Mahmoud H Abdou; M Azam Hadi
Journal:  Tex Heart Inst J       Date:  2019-02-01

4.  Non-cytopathic infection of rhabdomyosarcoma cells by coxsackie B5 virus.

Authors:  E Argo; B Gimenez; P Cash
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Evaluation of coxsackievirus infection in children with human immunodeficiency virus type 1-associated cardiomyopathy.

Authors:  Hal B Jenson; Charles J Gauntt; Kirk A Easley; Jane Pitt; Steven E Lipshultz; Kenneth McIntosh; William T Shearer
Journal:  J Infect Dis       Date:  2002-05-31       Impact factor: 5.226

6.  Kinetic and structural analysis of coxsackievirus B3 receptor interactions and formation of the A-particle.

Authors:  Lindsey J Organtini; Alexander M Makhov; James F Conway; Susan Hafenstein; Steven D Carson
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

7.  Evidence for a group-specific enteroviral antigen(s) recognized by human T cells.

Authors:  M A Beck; S M Tracy
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

8.  Rapidly progressive encephalopathy caused by Coxsackie meningoencephalitis in an elderly male.

Authors:  Masoom Desai; Melissa Motta
Journal:  J Neurovirol       Date:  2018-10-05       Impact factor: 2.643

9.  Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins.

Authors:  Stephanie J Bissel; Caitlin C Winkler; Joseph DelTondo; Guoji Wang; Karl Williams; Clayton A Wiley
Journal:  Neuropathology       Date:  2014-04-07       Impact factor: 1.906

10.  Neonatal coxsackie B virus infection-a treatable disease?

Authors:  Penelope A Bryant; David Tingay; Peter A Dargaville; Mike Starr; Nigel Curtis
Journal:  Eur J Pediatr       Date:  2004-02-18       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.